Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry

Proteomics

Volumn 13, Issue 16, 2013, Pages 2512-2525

  Hernychova, Lenka ^a   Man, Petr ^b,c   Verma, Chandra ^d,e,f   Nicholson, Jude ^g   Sharma, Carrie Anne ^g   Ruckova, Eva ^a   Teo, Jin Yuan ^d   Ball, Kathryn ^g   Vojtesek, Borek ^a   Hupp, Ted R ^a,g  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d BIOINFORMATICS INSTITUTE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Allostery; Biomedicine; Cancer; Deuterium exchange; MDM2; P53

Indexed keywords

NUTLIN 3; PEPSIN A; PEPTIDOMIMETIC AGENT; PROTEIN MDM2; PROTEIN P53;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; DEUTERIUM HYDROGEN EXCHANGE; HYDROPHOBICITY; LIGAND BINDING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN LOCALIZATION;

EID: 84881508478     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300029     Document Type: Article

References (35)

1. Ponnuswamy, A., Hupp, T., Fahraeus, R., Concepts in MDM2 signaling: allosteric regulation and feedback loops. Genes Cancer 2012, 3, 291-297.
2. Lane, D. P., Madhumalar, A., Lee, A. P., Tay, B. H. et al., Conservation of all three p53 family members and MDM2 and MDM4 in the cartilaginous fish. Cell Cycle 2011, 10, 4272-4279.
3. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B. et al., Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
4. Uhrinova, S., Uhrin, D., Powers, H., Watt, K. et al., Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J. Mol. Biol. 2005, 350, 587-598.
5. Schon, O., Friedler, A., Freund, S., Fersht, A. R., Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. 2004, 336, 197-202.
6. Yu, G. W., Allen, M. D., Andreeva, A., Fersht, A. R., Bycroft, M., Solution structure of the C4 zinc finger domain of HDM2. Protein Sci. 2006, 15, 384-389.
7. Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., Wright, P. E., Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol. 2006, 363, 433-450.
8. Worrall, E. G., Worrall, L., Blackburn, E., Walkinshaw, M., Hupp, T. R., The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J. Mol. Biol. 2010, 398, 414-428.
9. Worrall, E. G., Wawrzynow, B., Worrall, L., Walkinshaw, M. et al., Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J. Chem. Biol. 2009, 2, 113-129.
10. Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R., Ball, K. L., Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 2006, 23, 251-263.
11. Yu, G. W., Rudiger, S., Veprintsev, D., Freund, S. et al., The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 2006, 103, 1227-1232.
12. Macias, E., Jin, A., Deisenroth, C., Bhat, K. et al., An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 2010, 18, 231-243.
13. Poyurovsky, M. V., Jacq, X., Ma, C., Karni-Schmidt, O. et al., Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol. Cell 2003, 12, 875-887.
14. Wawrzynow, B., Zylicz, A., Wallace, M., Hupp, T., Zylicz, M., MDM2 chaperones the p53 tumor suppressor. J. Biol. Chem. 2007, 282, 32603-32612.
15. Stevens, C., Pettersson, S., Wawrzynow, B., Wallace, M. et al., ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1. FEBS J. 2008, 275, 4875-4886.
16. Gajjar, M., Candeias, M. M., Malbert-Colas, L., Mazars, A. et al., The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012, 21, 25-35.
17. Candeias, M. M., Malbert-Colas, L., Powell, D. J., Daskalogianni, C. et al., P53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 2008, 10, 1098-1105.
18. Picksley, S. M., Vojtesek, B., Sparks, A., Lane, D. P., Immunochemical analysis of the interaction of p53 with MDM2-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994, 9, 2523-2529.
19. Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D. et al., The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 2002, 277, 28446-28458.
20. Sibille, N., Bernado, P., Structural characterization of intrinsically disordered proteins by the combined use of NMR and SAXS. Biochem. Soc. Trans. 2012, 40, 955-962.
21. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D. et al., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
22. Nicholson, J., Neelagandan, K., Huart, A. S., Ball, K. et al., An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis. J. Proteome Res. 2012, 11, 5464-5478.
23. Glasoe, P., Long, F., Use of glass electrodes to measure acidities in deuterium oxide. J. Phys. Chem. 1960, 64, 188-189.
24. Bottger, V., Bottger, A., Howard, S. F., Picksley, S. M. et al., Identification of novel mdm2 binding peptides by phage display. Oncogene 1996, 13, 2141-2147.
25. Brown, C. J., Dastidar, S. G., Quah, S. T., Lim, A. et al., C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One 2011, 6, e24122.
26. Dastidar, S. G., Lane, D. P., Verma, C. S., Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics 2009, 10(Suppl 15), S6.
27. Dastidar, S. G., Lane, D. P., Verma, C. S., Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J. Am. Chem. Soc. 2008, 130, 13514-13515.
28. Graf, C., Stankiewicz, M., Nikolay, R., Mayer, M. P., Insights into the conformational dynamics of the E3 ubiquitin ligase CHIP in complex with chaperones and E2 enzymes. Biochemistry 2010, 49, 2121-2129.
29. Riedinger, C., Noble, M. E., Wright, D. J., Mulks, F. et al., Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chem. Biol. Drug Des. 2011, 77, 301-308.
30. Madhumalar, A., Lee, H. J., Brown, C. J., Lane, D., Verma, C., Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle 2009, 8, 2828-2836.
31. Dastidar, S. G., Raghunathan, D., Nicholson, J., Hupp, T. R. et al., Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle 2011, 10, 82-89.
32. McCoy, M. A., Gesell, J. J., Senior, M. M., Wyss, D. F., Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc. Natl. Acad. Sci. USA 2003, 100, 1645-1648.
33. Vogel, S. M., Bauer, M. R., Joerger, A. C., Wilcken, R. et al., Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc. Natl. Acad. Sci. USA 2012, 109, 16906-16910.
34. Darragh, J., Hunter, M., Pohler, E., Nelson, L. et al., The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury. FEBS J. 2006, 273, 1930-1947.
35. Pettersson, S., Sczaniecka, M., McLaren, L., Russell, F. et al., Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the notch signalling pathway. Biochem. J. 2013, 450, 523-536.